Top Page
Tsumura & Co
(4540)
Tsumura & Co (4540) vs. iShares MSCI Japan ETF (EWJ)
Tsumura & Co Business Overview & Revenue Model
Tsumura & Co Financial Statement Overview
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 189.50B | 181.09B | 150.84B | 140.04B | 129.55B | 130.88B |
| Gross Profit | 90.20B | 90.58B | 68.82B | 68.28B | 66.47B | 74.93B |
| EBITDA | 53.75B | 57.25B | 34.82B | 34.03B | 34.92B | 29.36B |
| Net Income | 29.01B | 32.43B | 16.71B | 16.48B | 18.84B | 15.33B |
Balance Sheet | ||||||
| Total Assets | 549.68B | 464.38B | 428.25B | 396.81B | 350.98B | 319.06B |
| Cash, Cash Equivalents and Short-Term Investments | 69.48B | 73.23B | 78.08B | 94.75B | 67.55B | 61.31B |
| Total Debt | 135.41B | 70.80B | 80.10B | 80.05B | 50.00B | 53.09B |
| Total Liabilities | 211.04B | 134.27B | 132.89B | 124.56B | 92.87B | 85.89B |
| Stockholders Equity | 305.33B | 300.53B | 270.80B | 252.05B | 239.77B | 217.79B |
Cash Flow | ||||||
| Free Cash Flow | -21.99B | 6.23B | -11.21B | 4.23B | 11.14B | 7.15B |
| Operating Cash Flow | 15.40B | 33.82B | 5.61B | 16.45B | 21.31B | 16.10B |
| Investing Cash Flow | -46.44B | -24.97B | -19.35B | -15.49B | -9.11B | 215.00M |
| Financing Cash Flow | 20.41B | -19.87B | -4.42B | 24.42B | -8.18B | -17.99B |
Tsumura & Co Technical Analysis
Tsumura & Co Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
80 Outperform | ¥148.04B | 93.62 | -2.58% | 4.16% | -5.99% | -96.04% | |
77 Outperform | ¥331.78B | 9.44 | ― | 2.12% | 4.07% | 22.59% | |
73 Outperform | ¥440.40B | 15.43 | 7.11% | 2.43% | 3.53% | 38.23% | |
73 Outperform | ¥118.59B | 12.60 | 4.81% | 2.34% | 4.35% | 48.30% | |
69 Neutral | ¥284.00B | 7.12 | 9.05% | 3.30% | 10.51% | 9.62% | |
52 Neutral | ¥18.77B | 72.72 | ― | 3.65% | 9.53% | -155.76% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
Tsumura & Co Corporate Events
Tsumura & Co. has concluded a contract to acquire shares of Yomeishu Seizo Co., Ltd., aligning the deal with its long-term TSUMURA VISION “Cho-WA” 2031 strategy. The vision emphasizes contributing to a healthier society by developing evidence-based diagnostic methods for pre-symptomatic diseases and delivering Kampo and traditional Chinese medicine solutions tailored to personal health conditions.
The acquisition supports Tsumura’s ambition to expand its footprint in traditional medicine while reinforcing a corporate culture that values dialogue and employee potential. By integrating Yomeishu Seizo into its broader strategy, Tsumura aims to strengthen its unique positioning in Kampo and traditional Chinese medicine, enhancing its role in preventive healthcare and personalized well-being services.
The most recent analyst rating on (JP:4540) stock is a Buy with a Yen4762.00 price target. To see the full list of analyst forecasts on Tsumura & Co stock, see the JP:4540 Stock Forecast page.
Tsumura & Co. has agreed a four-party master deal with Yomeishu Seizo, Reno and Yuzawa under which Yomeishu will be taken private, restructured, and eventually become wholly owned by Tsumura via a staged tender offer, squeeze-out, asset separation, and share transfers. After Reno’s tender offer and squeeze-out concentrate Yomeishu’s shares in Yuzawa, non-operating assets will be carved out through dividends or splits, and Tsumura will then acquire all remaining Yomeishu shares from Yuzawa for ¥6.8 billion around July–August 2026.
The transaction is central to Tsumura’s strategy to build a multi-pillar business portfolio and reinforce its stable earnings base by expanding beyond prescription Kampo into the broader healthcare product field where Yomeishu is strong. By refocusing Yomeishu’s operations on its flagship “Yomeishu” brand and reallocating management resources to that core business before the final share transfer, Tsumura expects to enhance Yomeishu’s medium- to long-term corporate value and realize synergies and complementary strengths within the Kampo and healthcare markets.
The most recent analyst rating on (JP:4540) stock is a Buy with a Yen4762.00 price target. To see the full list of analyst forecasts on Tsumura & Co stock, see the JP:4540 Stock Forecast page.
Tsumura & Co. released supplementary materials for the third quarter of the fiscal year ending March 31, 2026, detailing consolidated financial statements, sales by business and product group, and quarterly performance data, with a particular focus on the sales and growth of 129 prescription Kampo formulations. The company also announced changes in its consolidation scope and reporting format, notably shifting to consolidate first the balance sheet and now, from the third quarter, the income statement of its Shanghai Hongqiao traditional Chinese drug pieces subsidiary, a move that is likely to provide a more complete view of the group’s financial position and performance and may underscore the growing strategic importance of its Chinese herbal medicine operations within the overall business.
The most recent analyst rating on (JP:4540) stock is a Hold with a Yen4584.00 price target. To see the full list of analyst forecasts on Tsumura & Co stock, see the JP:4540 Stock Forecast page.
Tsumura & Co. reported consolidated net sales of ¥145.2 billion for the first nine months of the fiscal year ending March 31, 2026, a 6.1% year-on-year increase, but saw declines in profitability, with operating profit down 10.9%, ordinary profit down 9.2%, and profit attributable to owners of parent falling 12.9% to ¥23.2 billion; basic earnings per share dropped to ¥309.60 and the equity ratio weakened to 55.5% as total assets expanded. Despite the profit pressures, the company maintained its dividend policy with an interim payout of ¥68 per share and is forecasting a slight increase in the full-year dividend to ¥144 per share, while keeping its full-year guidance unchanged at ¥198.0 billion in net sales and a 25.1% decline in profit attributable to owners of parent, signaling a cautious stance amid rising costs or other margin challenges but continued commitment to shareholder returns.
The most recent analyst rating on (JP:4540) stock is a Hold with a Yen4584.00 price target. To see the full list of analyst forecasts on Tsumura & Co stock, see the JP:4540 Stock Forecast page.
Tsumura & Co. clarified that recent reports in the digital and print editions of The Nikkei about its involvement in a potential take-private transaction for Yomeishu Seizo Co., Ltd. did not originate from the company itself. The company acknowledged that it is considering the reported matters but emphasized that no decisions have been made, and it pledged to disclose any material developments in a timely and appropriate manner, signaling that discussions remain at a preliminary stage and that stakeholders should not assume a finalized deal.
The most recent analyst rating on (JP:4540) stock is a Hold with a Yen4584.00 price target. To see the full list of analyst forecasts on Tsumura & Co stock, see the JP:4540 Stock Forecast page.
Tsumura & Co. has entered into a large unsecured syndicated loan agreement with a bank group led by MUFG Bank to finance active investment in equipment and business initiatives tied to its long-term management vision, including sustaining growth in its domestic operations and expanding its presence in China. The agreement, split into two tranches totaling ¥50 billion and maturing in 2033 and 2036, includes financial covenants requiring the company to maintain at least 75% of specified consolidated net asset levels and to avoid recording operating losses for two consecutive fiscal years, underscoring both the lender’s risk controls and the company’s commitment to financial discipline, although Tsumura says the deal will have no material impact on its current earnings outlook.
The most recent analyst rating on (JP:4540) stock is a Hold with a Yen4226.00 price target. To see the full list of analyst forecasts on Tsumura & Co stock, see the JP:4540 Stock Forecast page.